CEBP  Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Willis, D. B.
Right arrow Articles by Colburn, N. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Willis, D. B.
Right arrow Articles by Colburn, N. H.
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 972-978, October 2002
© 2002 American Association for Cancer Research


Meeting Report

Molecular Targets for Cancer Prevention

A Meeting Review of the Third American Cancer Society-Schilling Research Conference

Dawn B. Willis1 and Nancy H. Colburn

Research Department, American Cancer Society, Inc., Atlanta, Georgia 30329 [D. B. W.], and Gene Regulation Section, National Cancer Institute, Frederick, Maryland 21702 [N. H. C.]

Abstract

The American Cancer Society-Schilling Research Conference, held at Seascape, California, on October 26–29, 2000, convened over 25 experts in interdisciplinary fields to discuss the prospects for molecular targets of cancer prevention. Promising molecular targets fell into four main classes: (a) genes in which altered expression or activation drives induction of cancer and for which inhibitor drugs are commercially available; (b) genes in which altered expression or activation is shown to be causal in two or more models but for which inhibitor/modulator drugs are not commercially available; (c) molecular targets for which drugs are available but of which the causal significance is unknown; and (d) known and unknown molecular targets of preventive dietary modifications. Recent developments in genomics and proteomics have brought us to the threshold of an extraordinarily promising era in our battle to reduce the burden of cancer. Knowledge of genes that drive or prevent cancer progression and genes that specify cancer susceptibility should bring molecular-targeted interventions to the individuals who will benefit most.




This article has been cited by other articles:


Home page
ChestHome page
G. S. Omenn
Human Lung Cancer Chemoprevention Strategies: Parker B. Francis Lecture
Chest, May 1, 2004; 125(5_suppl): 123S - 127S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.